ANIKAnika Therapeutics, Inc.
- GlobeNewswire
Anika Reports Third Quarter 2026 Financial Results
Revenue Increased 10% Year Over Year, Led by 17% Commercial Channel Growth Including More Than 30% Growth in IntegrityTM Revenue Secured New 10-Year Hyvisc® Partnership with Enhanced Economics; Reintroduced Hyaff ...
- GlobeNewswire
Anika to Issue Third Quarter 2026 Financial Results on Friday, November 6, 2026
BEDFORD, Mass., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ:ANIK), a global joint preservation company in early intervention orthopedics, announced today that it will issue its third quarter ...
- Analyst Upgrades
B. Riley Securities Assumes Anika Therapeutics at Buy, Raises Price Target to $23
B. Riley Securities analyst Madison El-Saadi assumes Anika Therapeutics with a Buy rating and raises Price Target to $23. ...
- GlobeNewswire
Every Few Decades, Aesthetics Gets a New Category. One Preclinical Company Thinks Its Extra Cellular Matrix Platform Could Create the Next One
NEW YORK, Aug. 04, 2026 (GLOBE NEWSWIRE) -- American News Group News Commentary - The multi-billion-dollar medical aesthetics market is built on a handful of category-defining breakthroughs. The neuromodulator ...
- Analyst Upgrades
B. Riley Securities Maintains Buy on Anika Therapeutics, Raises Price Target to $21
B. Riley Securities analyst Anderson Schock maintains Anika Therapeutics with a Buy and raises the price target from $18 to $21. ...
- GlobeNewswire
Anika Reports Second Quarter 2026 Financial Results
Commercial Channel Revenue Increased 17% to a Record $13.9 Million Delivered $3.3 Million of Net Income, 65% Gross Margin, and $7.1 Million of Adjusted EBITDA, Highest Since 2020 Raising Full-Year 2026 Financial ...
- GlobeNewswire
Anika to Issue Second Quarter 2026 Financial Results on Wednesday, July 29, 2026
BEDFORD, Mass., July 15, 2026 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ:ANIK), a global joint preservation company in early intervention orthopedics, announced today that it will issue its second quarter ...
- GlobeNewswire
Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BEDFORD, Mass., June 05, 2026 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ:ANIK), a global leader in the osteoarthritis pain management and regenerative solutions spaces focused on early intervention ...
- GlobeNewswire
TELA Bio Announces Strategic Board Refreshment with Four Highly Experienced Commerical Leaders to Accelerate Growth and Drive Path to Profitability; The Company Also Reports Preliminary First Quarter 2026 Revenues
MALVERN, Pa., April 30, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced a ...
- GlobeNewswire
Anika Reports First Quarter 2026 Financial Results
Grew total company revenue 13%, driven by Commercial Channel strength and favorable OEM Channel order timing Delivered 64% gross margin, +8 points year over year, driven by improved operational execution Operational ...
- GlobeNewswire
Xilio Therapeutics Appoints Cheryl R. Blanchard, Ph.D. to its Board of Directors
WALTHAM, Mass., April 16, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (NASDAQ:XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with ...
- GlobeNewswire
Anika to Issue First Quarter 2026 Financial Results on Wednesday, April 29, 2026
BEDFORD, Mass., April 15, 2026 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ:ANIK), a global joint preservation company in early intervention orthopedics, announced today that it will issue its first quarter ...
- GlobeNewswire
Telix Strengthens Board with Additional Director Appointments
MELBOURNE, Australia and INDIANAPOLIS, April 09, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ:TLX, "Telix") today announces two additional Non-Executive Director (NED) appointments, ...
- GlobeNewswire
Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BEDFORD, Mass., April 03, 2026 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ:ANIK), a global leader in the osteoarthritis pain management and regenerative solutions spaces focused on early intervention ...
- GlobeNewswire
Anika Reports Fourth Quarter and Full Year 2025 Financial Results
Met 2025 revenue and exceeded revised adjusted EBITDA; reaffirms 2026 revenue and sets adjusted EBITDA target Commercial Channel grew 22% and 15% for Q4 and full year, respectively Generated $11.2 million operating ...
- GlobeNewswire
Anika To Present at the Canaccord Genuity 2026 Musculoskeletal Conference
BEDFORD, Mass., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ:ANIK), a global joint preservation company in early intervention orthopedics, today announced that Steve Griffin, President and CEO of ...
- GlobeNewswire
Anika to Issue Fourth Quarter and Year-End 2025 Financial Results on Thursday, February 26, 2026
BEDFORD, Mass., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ:ANIK), a global joint preservation company in early intervention orthopedics, announced today that it will issue its fourth quarter and ...
- PR Newswire
Lumicell Appoints Biotech and Medtech Leader Cheryl R. Blanchard, Ph.D., to Board of Directors
Lumicell, Inc., a leader in developing innovative fluorescence-guided imaging technologies for cancer detection, today announced the appointment of... ...
- Analyst Upgrades
Barrington Research Maintains Outperform on Anika Therapeutics, Maintains $16 Price Target
Barrington Research analyst Michael Petusky maintains Anika Therapeutics with a Outperform and maintains $16 price target. ...
- GlobeNewswire
Anika Therapeutics Announces Leadership Transition
Stephen (Steve) Griffin, Current Chief Financial Officer and Chief Operating Officer, Appointed President and Chief Executive OfficerCheryl Blanchard to Become Executive Chair of the Board of Directors BEDFORD, Mass., ...
- BusinessWire
ANIK Investigation: Investors Encouraged to Contact Kirby McInerney LLP
The law firm of Kirby McInerney LLP reminds investors its investigation on behalf of Anika Therapeutics, Inc. ("Anika" or the "Company") (NASDAQ:ANIK) investors concerning the Company's and/or members of its senior ...
- GlobeNewswire
Anika Therapeutics, Inc. INVESTIGATION: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud on behalf of Investors ANIK
NEW YORK, Dec. 05, 2025 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating potential claims against Anika Therapeutics, Inc. ("Anika" or the "Company") (NASDAQ:ANIK). The investigation concerns ...
- Analyst Upgrades
Barrington Research Maintains Outperform on Anika Therapeutics, Raises Price Target to $16
Barrington Research analyst Michael Petusky maintains Anika Therapeutics with a Outperform and raises the price target from $15 to $16. ...
- GlobeNewswire
Anika Reports Third Quarter 2025 Financial Results
Commercial Channel revenue up 22% with continued strong Integrity™ Implant System and Hyalofast® growth, and double-digit International OA Pain Management growth Third and final Hyalofast PMA module filed ...
- GlobeNewswire
Anika Therapeutics Reports Filing of Final PMA Module for Hyalofast® Cartilage Repair Scaffold and Data from U.S. Pivotal FastTRACK Phase III Study
BEDFORD, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ:ANIK), a global leader in joint preservation and regenerative solutions, announced that it filed the third and final module of its ...